ArticleJournal of translational medicine2026
Restoring brain wiring, mobility, sleep, and lifespan with a novel repurposed modulator of voltage-gated K
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVoltage-gated K+ channels (Kv) regulate various essential brain functions. Cognitive impairment, intellectual disability, and sleep disruption are prevalent in Kv1.1- and Kv1.2-related channelopathies, yet the mechanistic basis is unresolved and no symptom-specific repurposing candidates for pharmacotherapy have been identified. Furthermore, the role Kv channels play in establishing synaptic wiring—the intricate network of neuron-to-neuron connections that underpins communication within the brain that is fundamental to cognitive functions—remains poorly understood at ultrastructural level.
methodWe employed a multidisciplinary experimental approach integrating ultrastructural, biochemical, electrophysiological and behavioral analyses to investigate the impact of Shaker K+ channel mutation on synaptic connections in the brain of Drosophila melanogaster flies Sh and to identify drugs with repurposing potential. In the protocerebrum, T-bars density and morphology was assessed using transmission electron microscopy while the concentration of the drug in the brain was measured by UHPLC–MS/MS. Survival and motor behavior were evaluated via lifespan and climbing assays, while sleep was quantified using the Drosophila Activity Monitoring System. The functional effects of the drug on ion channels were studied using two-electrode voltage-clamp in Xenopus laevis oocytes and whole-cell patch-clamp recordings in differentiated Neuro-2a cells. Finally, evoked post-synaptic potentials were recorded to assess neuromuscular transmission efficacy.
resultsMutant Sh flies exhibit impaired neuromuscular transmission, climbing ability, and sleep duration, ultimately shortening lifespan. We observed that all these abnormalities in Sh flies were significantly alleviated by administering low dose of ibuprofen, a widely used non-steroidal anti-inflammatory drug. Through high-resolution ultrastructural analyses, we discovered decreased density of T-bars with morphologically abnormal presynaptic bouton active zones in the brains of Sh flies which were restored by nanomolar concentrations of ibuprofen in their brains. Mechanistically, the drug increased the amplitude of both Shaker currents in Xenopus oocytes and voltage-gated K+ currents in Neuro-2a cells. Collectively, these results identify ibuprofen as a previously unrecognized modulator of Kv channels that restores neuronal network integrity compromised by Shaker K+ channel dysfunction, thereby normalizing neuromuscular signaling and enhancing motor performance, sleep, and longevity in Sh mutant flies. Notably, this study uncovers that genetically-induced dysfunction of Kv1 channels leads to disrupted brain wiring, highlighting the crucial role this K+ channel type plays in establishing proper neuron-to-neuron connections, and offer a pioneering treatment strategy for symptoms-targeted Kv1.1 channelopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.